Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Picankibart on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Picankibart is a biologic injection for adults with moderate-to-severe plaque psoriasis. It was developed in China by Innovent Biologics and is sold there as PECONDLE® (信美悦®). Once the starting doses are done, it is given only once every 12 weeks.
China's National Medical Products Administration (NMPA) approved it in November 2025 for:
It is a prescription immunology medicine and should be used under the care of a dermatologist.
Interleukin-23 (IL-23) is one of the main messengers that keeps psoriasis inflammation going. It switches on immune cells that release further signals, and these make skin cells multiply too quickly and pile up into plaques. Picankibart is a monoclonal antibody that binds the p19 part of IL-23, which is unique to that messenger, so IL-23 can no longer reach its receptor. Its Fc region has been engineered so it stays in the body longer, which is what allows the long 12-week gap between maintenance doses.
The phase 3 CLEAR-1 trial enrolled 500 Chinese adults with moderate-to-severe plaque psoriasis and was published in the Journal of the American Academy of Dermatology in 2026. At week 16, 80.3% of people on picankibart 200 mg reached PASI 90, meaning their psoriasis score improved by at least 90%, compared with 2.0% on placebo. 93.5% were rated clear or almost clear by their doctor, against 13.1% on placebo. These results held steady through week 52 on both 100 mg and 200 mg every 12 weeks.
A separate phase 2 study of 152 people, most of whom had already used an IL-17A biologic, looked at switching straight to picankibart. Among those whose psoriasis was not well controlled before the switch, 48.2% reached clear or almost-clear skin (with less than 3% of the body affected) by week 16, rising to 54.2% by week 44.
In the CLEAR-1 trial, the schedule was:
The dose your dermatologist prescribes should follow the Chinese prescribing information supplied with the pack.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Picankibart acts on the immune system, so the precautions below are the ones doctors normally follow with this kind of biologic. Full details are in the Chinese prescribing information.
Overall: the CLEAR-1 researchers reported that picankibart was well tolerated, with no new safety signals through 52 weeks. Innovent describes its safety profile as consistent with other IL-23p19 antibodies. Detailed side-effect percentages from CLEAR-1 were not available in the sources we reviewed. Safety in pregnancy, breastfeeding and children has not been established, so discuss these situations with your doctor.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. We also help patients import other psoriasis treatments, such as Bimzelx and Sotyktu.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The pens are stored and shipped as directed on the pack, using temperature-controlled shipping, and kept in their original box until use. Because the starting phase needs several pens and maintenance needs one or two every 12 weeks, we plan each order around the treatment calendar. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital or clinic on a valid specialist's prescription.
Skin specialists in Delhi treat many people with long-standing psoriasis, and our New Delhi dispatch point keeps transit times short.
Pens can be delivered to the clinic or hospital where the patient receives the injection.
Dermatologists in Bangalore can request the medicine for a named patient, with a written quote before any order is placed.
We time deliveries around the week 0, 4 and 8 starting doses so treatment begins on schedule.
Patients in Hyderabad can follow the same documented import route, with updates at each step.
Orders for Kolkata and the eastern states are shipped in temperature-controlled packaging.
With doses 12 weeks apart in maintenance, we help patients in Pune order well before each one is due.
The treating dermatologist can share the prescription and treatment history to begin the import.
Patients across Rajasthan can have the pens delivered to their dermatologist in Jaipur.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating centre.
We coordinate delivery to hospitals and skin clinics across Uttar Pradesh.
Patients in Kerala can receive the medicine at their hospital or clinic in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
